Paul Schimmel - Director, Atyr Pharma Inc
As of April 28, 2022
Paul Schimmel Net Worth
- Net worth is estimated to be at least $193.44M
- Owns at least 792,166 units of Atyr Pharma Inc stock
- Sold an estimated value of $30.74K in the last 7 years at Atyr Pharma Inc
Paul Schimmel Trading
- Largest purchase of shares was 500,000 units , worth over $2M on September 22, 2021
- Largest sale of shares was 8,447 units , worth over $30.74K on May 22, 2020
- In total has made about 30 transactions over 7 years
- Usually trades in April, with the busiest year in 2016
PAUL SCHIMMEL
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |
Paul Schimmel Mailing Address
- Mailing address is 88 Sidney St Cambridge MA 02139 MA
Atyr Pharma Inc Executive Compensation
Name |
Year
|
Salary
|
Other Earnings Plans or Compensations
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
---|---|---|---|---|---|---|---|
Sanjay S. Shukla, M.D., M.S. | 2020 | $470,250 | $223,369 | $381,811 | $223,369 | $8,427 | $1,083,857 |
Sanjay S. Shukla, M.D., M.S. | 2019 | $450,000 | $95,625 | $82,400 | $95,625 | $10,076 | $663,961 |
Jill M. Broadfoot | 2020 | $365,750 | $138,985 | $182,671 | $138,985 | $11,374 | $698,780 |
Jill M. Broadfoot | 2019 | $350,000 | $59,500 | $20,600 | $59,500 | $11,594 | $454,624 |
Nancy E. Denyes | 2020 | $350,075 | $116,400 | $148,121 | $116,400 | $10,661 | $625,257 |
Nancy E. Denyes | 2019 | $335,000 | $49,831 | $51,500 | $49,831 | $12,932 | $449,263 |
No matching records found |
Source: https://www.sec.gov/Archives/edgar/data/1339970/000156459021014935/life-def14a_20210428.htm
Atyr Pharma Inc Insider Trading
- The most recent transaction was 1,923 units bought on January 18, 2022 by Marie Jill Broadfoot worth over $12.98K
- In the last 7 years, insiders at Atyr Pharma Inc sold an estimated value of $3.13M and bought an estimated value of $16.44M
- The most active traders are Paul Schimmel, Director, Sanjay Shukla, President and CEO, and John Mendlein, Director
- Insider trading is most common in May, with the busiest year in 2016
aTYR PHARMA INC Insider Trades
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |